Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Research

Immunological characteristics of immunogenic cell death genes and malignant progression driving roles of TLR4 in anaplastic thyroid carcinoma

Authors: Tong Xu, Chaozhuang Zhu, Feifeng Song, Wanli Zhang, Mengnan Yuan, Zongfu Pan, Ping Huang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Anaplastic thyroid carcinoma (ATC) was a rare malignancy featured with the weak immunotherapeutic response. So far, disorders of immunogenic cell death genes (ICDGs) were identified as the driving factors in cancer progression, while their roles in ATC remained poorly clear. Datasets analysis identified that most ICDGs were high expressed in ATC, while DE-ICDGs were located in module c1_112, which was mainly enriched in Toll-like receptor signalings. Subsequently, the ICD score was established to classify ATC samples into the high and low ICD score groups, and function analysis indicated that high ICD score was associated with the immune characteristics. The high ICD score group had higher proportions of specific immune and stromal cells, as well as increased expression of immune checkpoints. Additionally, TLR4, ENTPD1, LY96, CASP1 and PDIA3 were identified as the dynamic signature in the malignant progression of ATC. Notably, TLR4 was significantly upregulated in ATC tissues, associated with poor prognosis. Silence of TLR4 inhibited the proliferation, metastasis and clone formation of ATC cells. Eventually, silence of TLR4 synergistically enhanced paclitaxel-induced proliferation inhibition, apoptosis, CALR exposure and release of ATP. Our findings highlighted that the aberrant expression of TLR4 drove the malignant progression of ATC, which contributed to our understanding of the roles of ICDGs in ATC.
Appendix
Available only for authorised users
Literature
45.
go back to reference Metovic J, Vignale C, Annaratone L, Osella-Abate S, Maletta F, et al. The Oncocytic variant of poorly differentiated thyroid carcinoma shows a specific Immune-related gene expression Profile. J Clin Endocrinol Metab. 2020;105(12). https://doi.org/10.1210/clinem/dgaa655. Metovic J, Vignale C, Annaratone L, Osella-Abate S, Maletta F, et al. The Oncocytic variant of poorly differentiated thyroid carcinoma shows a specific Immune-related gene expression Profile. J Clin Endocrinol Metab. 2020;105(12). https://​doi.​org/​10.​1210/​clinem/​dgaa655.
47.
go back to reference Schulten HJ, Hussein D, Al-Adwani F, Karim S, Al-Maghrabi J, et al. Microarray expression profiling identifies genes, including cytokines, and biofunctions, as diapedesis, associated with a brain Metastasis from a papillary thyroid carcinoma. Am J Cancer Res. 2016;6(10):2140–61.PubMedPubMedCentral Schulten HJ, Hussein D, Al-Adwani F, Karim S, Al-Maghrabi J, et al. Microarray expression profiling identifies genes, including cytokines, and biofunctions, as diapedesis, associated with a brain Metastasis from a papillary thyroid carcinoma. Am J Cancer Res. 2016;6(10):2140–61.PubMedPubMedCentral
48.
go back to reference Kure S, Chiba T, Ebina A, Toda K, Jikuzono T, et al. Correlation between low expression of protein disulfide isomerase A3 and lymph node Metastasis in papillary thyroid carcinoma and poor prognosis: a clinicopathological study of 1,139 cases with long-term follow-up. Endocr J. 2022;69(3):273–81. https://doi.org/10.1507/endocrj.EJ21-0394.CrossRefPubMed Kure S, Chiba T, Ebina A, Toda K, Jikuzono T, et al. Correlation between low expression of protein disulfide isomerase A3 and lymph node Metastasis in papillary thyroid carcinoma and poor prognosis: a clinicopathological study of 1,139 cases with long-term follow-up. Endocr J. 2022;69(3):273–81. https://​doi.​org/​10.​1507/​endocrj.​EJ21-0394.CrossRefPubMed
Metadata
Title
Immunological characteristics of immunogenic cell death genes and malignant progression driving roles of TLR4 in anaplastic thyroid carcinoma
Authors
Tong Xu
Chaozhuang Zhu
Feifeng Song
Wanli Zhang
Mengnan Yuan
Zongfu Pan
Ping Huang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11647-y

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine